Literature DB >> 24080650

One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.

C Clavel-Osorio1, F Cazassus, S Stegmann, P Huc-Anaïs, D Lecam, G Peytavin.   

Abstract

We describe the pharmacokinetics of raltegravir of a preterm newborn after short-course treatment of the mother tested HIV + the day of delivery. At age 1 month, the circulating concentration of raltegravir in the newborn was 29 ng/ml (the IC95 of RAL against HIV-1 is 15 ng/ml). Raltegravir should therefore be considered a potential transplacental postexposure prophylaxis for HIV-1 and an alternative to the use of boosted lopinavir in this context.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24080650      PMCID： PMC3837897          DOI： 10.1128/AAC.01349-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

Authors:  Albane Simon; Josiane Warszawski; Dulanjalee Kariyawasam; Jerome Le Chenadec; Valerie Benhammou; Paul Czernichow; Frantz Foissac; Kathleen Laborde; Jean-Marc Tréluyer; Ghislaine Firtion; Inès Layouni; Martine Munzer; Françoise Bavoux; Michel Polak; Stéphane Blanche
Journal:  JAMA       Date:  2011-07-06       Impact factor: 56.272

2.  The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver.

Authors:  Shogo J Miyagi; Abby C Collier
Journal:  Drug Metab Dispos       Date:  2011-01-25       Impact factor: 3.922

3.  Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

Authors:  Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

4.  Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Authors:  M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

5.  Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group.

Authors:  L Mandelbrot; M J Mayaux; A Bongain; A Berrebi; Y Moudoub-Jeanpetit; J L Bénifla; N Ciraru-Vigneron; J Le Chenadec; S Blanche; J F Delfraissy
Journal:  Am J Obstet Gynecol       Date:  1996-09       Impact factor: 8.661
  5 in total
  3 in total

1.  Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.

Authors:  Bassam H Rimawi; Erica Johnson; Augustine Rajakumar; Sijia Tao; Yong Jiang; Scott Gillespie; Raymond F Schinazi; Mark Mirochnick; Martina L Badell; Rana Chakraborty
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Raltegravir pharmacokinetics in neonates following maternal dosing.

Authors:  Diana F Clarke; Edward P Acosta; Matthew L Rizk; Yvonne J Bryson; Stephen A Spector; Lynne M Mofenson; Edward Handelsman; Hedy Teppler; Carolee Welebob; Deborah Persaud; Mae P Cababasay; JiaJia Wang; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

3.  Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).

Authors:  Diana F Clarke; Edward P Acosta; Mae Cababasay; Jiajia Wang; Anne Chain; Hedy Teppler; Stephanie Popson; Bobbie Graham; Betsy Smith; Rohan Hazra; Kat Calabrese; Yvonne Bryson; Stephen A Spector; Jos Lommerse; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.